Latest Market Entry News

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Janison Education Group posted a 3% revenue rise to $48.1 million in FY26, underpinned by international contract expansion and AI innovation, despite margin pressure from onboarding costs.

Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.

Andromeda Metals has successfully produced 4N High Purity Alumina (HPA) with 99.9986% purity at continuous pilot scale, marking a crucial step towards commercialisation and customer evaluation under a strategic supply agreement with Traxys.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Aurora Labs posted a 36% increase in net loss to $5.1 million for FY2026 despite securing key defence contracts and partnerships. The company is transitioning from R&D to early commercialisation of its micro gas turbine propulsion systems, backed by a $5.5 million capital raise and government grants.

AnteoTech has formalised a strategic alliance with South Korea’s Xerabrid to co-develop and commercialise a breakthrough battery separator combining their proprietary technologies, targeting high-performance applications in eVTOL, EVs, and consumer electronics.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

Dusk Group delivered record FY26 sales and underlying EBIT growth, driven by product rejuvenation and online momentum, while preparing for international expansion amid ACCC proceedings.